WO2006125450A1 - Rectal and vaginal suppositories containing misoprostol - Google Patents
Rectal and vaginal suppositories containing misoprostol Download PDFInfo
- Publication number
- WO2006125450A1 WO2006125450A1 PCT/EG2005/000033 EG2005000033W WO2006125450A1 WO 2006125450 A1 WO2006125450 A1 WO 2006125450A1 EG 2005000033 W EG2005000033 W EG 2005000033W WO 2006125450 A1 WO2006125450 A1 WO 2006125450A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- misoprostol
- vaginally
- tablets
- rectally
- rectal
- Prior art date
Links
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 title claims abstract description 6
- 229960005249 misoprostol Drugs 0.000 title claims abstract description 6
- 239000006215 rectal suppository Substances 0.000 title claims description 3
- 239000006216 vaginal suppository Substances 0.000 title claims description 3
- 239000000227 bioadhesive Substances 0.000 claims abstract description 3
- 229920001983 poloxamer Polymers 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 206010000210 abortion Diseases 0.000 abstract description 2
- 231100000176 abortion Toxicity 0.000 abstract description 2
- 230000000740 bleeding effect Effects 0.000 abstract description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229960000502 poloxamer Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
Definitions
- Misooprostol is considered a basic drug used in Obstetric practice in controlling postpartum and post-abortive bleeding, and induction of labor or abortion whenever indicated. Its basic route of administration is orally. However, the commercial tablets were tested via the oral cavity ( sublingually ), rectally or vaginally.
- the drug is prepared in a suppository form ( rectal and vaginal ) to be convenient for the patients. Moreover, some additives to enhance absorption as pluronics were added. Using bioadhesive technology is also included to facilitate maximal drug release and absorption.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
Abstract
Misoprostol is commonly used in obstetric practice for controlling post-partum and post-abortive bleeding, and inducing labor or abortion whenever indicated. Commonly, misoprostol is administered orally. Tests have been carried out to study the behaviour of the commercial tablets when administered sublingually, rectally or vaginally. However, the application of said tablets, either vaginally or rectally, in their current form is not easy, as the tablets are designed for oral use. The present invention concerns misoprostol-containing suppositories, which are more convenient, if used rectally resp. vaginally. Additionally, the suppositories contain at least one poloxamer to enhance absorption and at least one bioadhesive compound.
Description
Rectal and Vaginal Suppositories Containing Misoprostol
Technical Field:
Misooprostol is considered a basic drug used in Obstetric practice in controlling postpartum and post-abortive bleeding, and induction of labor or abortion whenever indicated. Its basic route of administration is orally. However, the commercial tablets were tested via the oral cavity ( sublingually ), rectally or vaginally.
Background:
Usage of the tablets in their current form vaginally or rectally is not perfect as these tablets are designed for oral use.
Disclosure of the invention:
In this current patent, the drug is prepared in a suppository form ( rectal and vaginal ) to be convenient for the patients. Moreover, some additives to enhance absorption as pluronics were added. Using bioadhesive technology is also included to facilitate maximal drug release and absorption.
Best mode for carrying out the invention:
Manufacturing this new foπnulation in a suppository form to be suited for vaginal as well as rectal application.
Industrial applicability:
It is easily manufactured in a suppository form.
Claims
Claims
- Creation of vaginal and rectal suppositories containing misoprostol - Adding bioadhesive substances and pluronics to the active ingredient
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EG2005050255 | 2005-05-26 | ||
| EG2005050255 | 2005-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006125450A1 true WO2006125450A1 (en) | 2006-11-30 |
Family
ID=37451640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EG2005/000033 WO2006125450A1 (en) | 2005-05-26 | 2005-10-01 | Rectal and vaginal suppositories containing misoprostol |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006125450A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2965750A1 (en) | 2014-07-11 | 2016-01-13 | Azanta A/S | Misoprostol dispersible tablet |
| WO2016004960A2 (en) | 2014-07-11 | 2016-01-14 | Azanta A/S | Misoprostol dispersible tablet |
| RU2580165C1 (en) * | 2015-04-03 | 2016-04-10 | государственное бюджетное образовательное учреждение высшего профессионального образования "Омская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОмГМА Минздрава России) | Method for termination of pregnancy in later stages on medical indications |
| RU2654707C1 (en) * | 2016-12-08 | 2018-05-22 | федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) | Combined method of induced abortion in the second trimester on medical indications |
| US10688072B2 (en) | 2014-07-11 | 2020-06-23 | Azanta Danmark A/S | Misoprostol dispersible tablet |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0864326A2 (en) * | 1997-03-12 | 1998-09-16 | Knoll Ag | Multiphasic preparation comprising an active agent |
| DE19812688A1 (en) * | 1998-03-23 | 1999-09-30 | Basf Ag | Solid dosage forms useful for slow release of drugs, fragrances, plant-treating agents, animal feed additives and food additives |
-
2005
- 2005-10-01 WO PCT/EG2005/000033 patent/WO2006125450A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0864326A2 (en) * | 1997-03-12 | 1998-09-16 | Knoll Ag | Multiphasic preparation comprising an active agent |
| DE19812688A1 (en) * | 1998-03-23 | 1999-09-30 | Basf Ag | Solid dosage forms useful for slow release of drugs, fragrances, plant-treating agents, animal feed additives and food additives |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2965750A1 (en) | 2014-07-11 | 2016-01-13 | Azanta A/S | Misoprostol dispersible tablet |
| WO2016004960A2 (en) | 2014-07-11 | 2016-01-14 | Azanta A/S | Misoprostol dispersible tablet |
| US10688072B2 (en) | 2014-07-11 | 2020-06-23 | Azanta Danmark A/S | Misoprostol dispersible tablet |
| US12005041B2 (en) | 2014-07-11 | 2024-06-11 | Azanta Danmark A/S | Misoprostol dispersible tablet |
| RU2580165C1 (en) * | 2015-04-03 | 2016-04-10 | государственное бюджетное образовательное учреждение высшего профессионального образования "Омская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОмГМА Минздрава России) | Method for termination of pregnancy in later stages on medical indications |
| RU2654707C1 (en) * | 2016-12-08 | 2018-05-22 | федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) | Combined method of induced abortion in the second trimester on medical indications |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE50111767D1 (en) | Solid oral dosage forms with sustained release of active ingredient and high mechanical stability | |
| EA200901393A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENES AND / OR ESTROGENS AND 5 METHYL- (6S) -TETRAHYDROPHOLATE | |
| EE05287B1 (en) | The so-called clopentanoindoles, their use in the manufacture of a medicament and the pharmaceutical composition containing them | |
| BR0111034A (en) | Compound, pharmaceutical composition, use of a compound, and methods for the treatment or prophylaxis of inflammatory conditions or diseases, for the treatment and / or prophylaxis of osteoporosis, and for the treatment of AIDS-related diseases. | |
| PE20010298A1 (en) | COMPOSITION FOR ORAL DOSAGE, INSTANTLY DISSOLVING | |
| NO20044731L (en) | Quinoline and Isoquinoline Derivatives Process for Preparation thereof and its Use as Inflammatory Inhibitors | |
| UY30462A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A TETRAHYDROPHOLIC ACID. | |
| EP1993567A4 (en) | Orally administrable gallium compositions and method of use | |
| HRP20030951B1 (en) | FORMULATIONS OF ONE-DAY DOSAGE OF OXYCODONE | |
| MXPA05002033A (en) | A PHARMACEUTICAL COMPOSITION. | |
| AR035637A1 (en) | BETAMIMETICOS OF LONG ACTION, PROCEDURE FOR ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS | |
| IS6828A (en) | New almond acid derivatives and their use as thrombin inhibitors | |
| MA28358A1 (en) | INHIBITORS OF HIV INTEGRASE | |
| MA28519B1 (en) | INHIBITORS OF HIV INTEGRASE | |
| WO2004103159A3 (en) | Methods for modulating endometrium | |
| IN2012DN06436A (en) | ||
| GEP20074224B (en) | Pharmaceutical compositions of sertaconazole for vaginal use | |
| DE60234725D1 (en) | Vaginally administrable composition for the treatment of uterine dysrhythmia | |
| IL151369A (en) | Use of tgf-beta antagonists for preparation of pharmaceutical compositions | |
| WO2006125450A1 (en) | Rectal and vaginal suppositories containing misoprostol | |
| MY148125A (en) | Compounds | |
| EP1756114A4 (en) | INHIBITORS OF HIV INTEGRASE | |
| BRPI0413446A (en) | hydroxyethylcellulose bioadhesive gel | |
| AR035064A1 (en) | 3- (1-METHYL-3-INDOLIL) -4- (1-METHYL-6-NITRO-3-INDOLIL) -1H-PIRROL-2,5-DIONA, AMORPHALLY, PROCESSES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT THE UNDERSTAND AND USE OF SUCH COMPOUND IN THE MANUFACTURE OF MEDICINES | |
| UY27596A1 (en) | ORAL FORMULATION OF PURISIMATE FLUDARA WITH RAPID RELEASE OF INGREDIENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: RU |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05787819 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112 (1) EPC, EPO FORM 1205A DATED 22.02.08. |